Literature DB >> 7082379

Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine.

N Y Liang, C O Rutledge.   

Abstract

Amphetamine-induced release of previously accumulated [3H]dopamine ([3H]DA) was compared to the release of [3H]DA produced by unlabelled DA and fenfluramine. Like unlabelled DA, amphetamine was more potent than fenfluramine in releasing [3H]DA in all tissue preparations (untreated, pargyline-treated, and pargyline- and reserpine-treated corpus striatal slices). In tissue treated with both reserpine and pargyline, benztropine greatly reduced the efflux of [3H]DA produced by amphetamine and unlabelled DA but had only a slight effect on fenfluramine-induced release of [3H]DA. In the same tissue preparation, Q10 values for the release of [3H]DA produced by 3 X 10(-7) M amphetamine (1.8) and 3 X 10(-6) M unlabelled DA (1.7) were similar to that for the spontaneous release of [3H]DA (1.7). However, when the concentrations of amphetamine and unlabelled DA were increased to 10(-4) M, the Q10 values for the release of [3H]DA were diminished at the lower temperatures. These results suggest that amphetamine may release [3H]DA by two mechanisms: (1) by accelerated exchange diffusion due to its use of the DA uptake carrier to enter into neurons (this would predominate at low concentrations of amphetamine), and (2) by passive entrance into neurons and displacement of [3H]DA from binding sites (this would predominate at high concentrations of amphetamine).

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082379     DOI: 10.1016/0006-2952(82)90332-x

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  29 in total

1.  Effect of temperature on dopamine transporter function and intracellular accumulation of methamphetamine: implications for methamphetamine-induced dopaminergic neurotoxicity.

Authors:  T Xie; U D McCann; S Kim; J Yuan; G A Ricaurte
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  Neurotoxicity of methamphetamine and methylenedioxymethamphetamine.

Authors:  L S Seiden; R Lew; J E Malberg
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

3.  Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.

Authors:  Justin R Nickell; Guangrong Zheng; Agripina G Deaciuc; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2010-09-28       Impact factor: 4.030

Review 4.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

5.  The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles.

Authors:  K Schwartz; A Weizman; M Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

6.  Repeated cocaine modifies the mechanism by which amphetamine releases dopamine.

Authors:  R C Pierce; P W Kalivas
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

7.  Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in mice.

Authors:  J P Q Zhu; W Xu; J A Angulo
Journal:  Neuroscience       Date:  2006-05-02       Impact factor: 3.590

8.  Lack of effect of kappa-opioid receptor agonism on long-term methamphetamine-induced neurotoxicity in rats.

Authors:  Kamisha L Johnson-Davis; Glen R Hanson; Kristen A Keefe
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

9.  Environmental enrichment decreases nicotine-induced hyperactivity in rats.

Authors:  Thomas A Green; Mary E Cain; Michael Thompson; Michael T Bardo
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

10.  Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate.

Authors:  T J Volz
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.